Cargando…
Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer
The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is est...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Second Military Medical University
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477778/ https://www.ncbi.nlm.nih.gov/pubmed/28642838 http://dx.doi.org/10.1016/j.ajur.2016.08.001 |